Bone Biologics (NASDAQ:BBLGW – Get Free Report) is expected to be announcing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.
Bone Biologics Price Performance
NASDAQ BBLGW opened at $31.95 on Friday. The firm’s fifty day moving average price is $19.20 and its two-hundred day moving average price is $15.34. Bone Biologics has a fifty-two week low of $8.30 and a fifty-two week high of $33.54.
Bone Biologics Company Profile
Bone Biologics, Inc is a clinical-stage biopharmaceutical company focused on developing protein-based therapeutics designed to promote bone healing and regeneration in acute and chronic orthopedic conditions. Its proprietary platform combines key osteogenic growth factors with engineered delivery matrices to support repair in complex fractures, spinal fusion procedures and non-union bone injuries. By targeting the biology of bone formation, the company aims to overcome limitations associated with autografts, allografts and synthetic implants.
The company’s lead candidate is advancing through preclinical evaluation, with studies assessing efficacy in animal models of fracture repair and spinal arthrodesis.
Featured Stories
- Five stocks we like better than Bone Biologics
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This makes me furious
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
